Uruga H et al (2013) found a high expression rate for these molecules in carcinoma patients diagnosed with PTTM, as the immunoreactive rates of VEGF, PDGF, TF, and osteopontin were 96.6%, 62%, 100%, and 62%, respectively.[2]. The gene discussed is SPP1; the disease is carcinoma.